Menarini to market, sell Moberg’ Kerasal Nail in South East Asia

Under the deal, Moberg Pharma has been granted Menarini Asia-Pacific the exclusive rights to market and sell Kerasal Nail in eight Southeast Asian countries.

The deal builds on an existing collaboration between the two company groups, which resulted in a successful launch of the product in Italy and a previous extension of the distribution agreement for China.

The eight Southeast Asian countries where Menarini will market and sell Kerasal Nail are Singapore, Taiwan, Indonesia, Philippines, Malaysia, Hong Kong, Thailand and Vietnam.

Moberg Pharma CEO Peter Wolpert said the company is happy to announce this agreement which meets one of its targets for 2014 – to enter the rapidly expanding Southeast Asian market.

"We enter this exciting opportunity together with Menarini Asia-Pacific – an ideal partner in the region," Wolpert said.

"The region has huge potential and the agreement will contribute to revenues and earnings already in 2014."

Kerasal Nail is a prescription-free, over-the-counter drug used to treat nail disease and is sold under the names Kerasal Nail, Naloc/Nalox and Emtrix.

Menarini Asia-Pacific CEO John Graham said the company seeks to introduce Kerasal Nail to consumers in Southeast Asia.

"The product has potential to contribute strongly to our expansion within the Consumer Health market, being a compelling non-prescription product offering rapid visual improvement and an effective solution for patients with nail fungus problems," Graham added.